Neurogene
NGNE
93 hedge funds and large institutions have $340M invested in Neurogene in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 7 closing their positions.
428% more call options, than puts
Call options by funds: $206K | Put options by funds: $39K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
28% more capital invested
Capital invested by funds: $265M → $340M (+$75.2M)
6% more funds holding
Funds holding: 88 → 93 (+5)
0.64% less ownership
Funds ownership: 107.2% → 106.56% (-0.64%)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$9.07M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.85M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$4M |
| 4 |
Jennison Associates
New York
|
+$3.46M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.39M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$4.37M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.41M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.25M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.83M |
NGNE Hedge Fund Activity: Q4 2025 in Review
93 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2025, worth a combined $340M — up 28% from $265M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NGNE positions and 7 closed out — a net gain of 7 holders — while 24 added to existing stakes and 29 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $9.07M. The largest seller was Millennium Management, cutting an estimated $4.39M.
- 93 institutional investors held Neurogene (NGNE) as of Q4 2025, up from 88 in Q3 2025.
- Funds reported $340M of Neurogene stock for Q4 2025, up 28% quarter-over-quarter.
- 14 funds opened new Neurogene positions in Q4 2025 and 7 closed out, a net change of +7 holders.
- The largest Neurogene buyer in Q4 2025 was Citadel Advisors, an estimated $9.07M added.
- The largest Neurogene seller in Q4 2025 was Millennium Management, an estimated $4.39M sold.
Based on aggregated 13F filings for Q4 2025.